

Supplementary Material

Combined multidisciplinary in/outpatient rehabilitation delays definite nursing home admission in advanced Parkinson's disease patients

Elien Steendam-Oldekamp,¹ Nico Weerkamp,² Judith M. Vonk³, Bastiaan R. Bloem,⁴ Teus van Laar¹

Correspondence: Elien Steendam-Oldekamp, University Medical Centre Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands.

Email: t.steendam@umcg.nl

Supplements

Therapy	Frequency (/week)	Hours/ week	Intervention type	Goals/targets
Physical therapy(1,2)	4	2-3	Individual and group therapy	<ol style="list-style-type: none">1. Improving transfers, posture, reaching and grasping, balance and walking.2. Maintaining and improving physical condition3. Preventing falls4. Improving mobility
Speech therapy(3)	1-2x	1	Individual	<ol style="list-style-type: none">1. Dysarthria and communication2. Dysphagia3. Salivation
Occupational therapy(4,5)	1	1.5	Individual	<ol style="list-style-type: none">1. Stimulation of self-management and empowerment2. Offering daily structure3. Coping with stress and time pressure4. Improving motor skills5. Improving focused attention6. Applying mindfulness-based cognitive strategies7. Coping with dual tasks8. Applying cues9. Optimisation of the physical habitat10. Counselling of caregivers
Professional activity coach	2-4	2-4	Group therapy	Activities which contribute to physical-, mental- and social well-being of the patients. These activities consist of: <ol style="list-style-type: none">1. leisure activities (e.g. music, painting)2. educational activities (e.g. computer lessons, traffic classes)3. ADL stimulating activities (e.g. cooking, shopping)4. practical activities (e.g. gardening, administration)

Social work	On demand (mean 2 hrs./week)	2	Individual and/or t partner/ caregiver	Psychosocial interventions
Dietician(6)	1-2	0.5	individual	<ol style="list-style-type: none"> 1. Inventory on burden of disease (patient and partner/caregiver) 2. Providing information on assistance-and support-networks 3. Exploring fields of interest of patient and/or partner/caregiver 4. Advise on coping with Parkinson's disease 1. weight loss and/or malnutrition 2. obstipation 3. intake of medication and response fluctuations 4. unwanted weight gain or obesity 5. chewing and swallowing disorders 6. delayed gastric emptying 7. orthostatic hypotension 8. role of vitamins and minerals

Table 1. Allied professional interventions at PFP 6 week customized intervention program, according the Dutch guidelines.

	<u>Intervention group (n=24)</u>		p-value *	<u>Control group (n=19)</u>		<u>Between group difference at 2 years</u>	
	Before intervention median (IQR)	After intervention median (IQR)		Before admission median (IQR)	After admission median (IQR)	p-value *	p-value **
Medication							
Cholinesterase inhibitors (n/%) <i>(Rivastigmine/Galantamine/ Donepezil)</i>	0 (0%)	13 (54.2%)	0.001	8 (42.1%)	4 (21.1%)	0.059	0.011
Atypical Antipsychotics (n/%) <i>(Clozapine, quetiapine)</i>	1 (4.2%)	4 (16.7%)	0.035	8 (42.1%)	4 (21.1%)	0.008	0.148
tricyclic antidepressants (n/%) <i>(amitriptyline, nortriptyline)</i>	0(0%)	4(16.7%)	0.059	4(21.1%)	0(0%)	0.046	0.065
Allied Therapies (used)							
Physiotherapy (n/%) <i>(mean (SD) minutes a week)</i>	5(20.8%) 23.1 (4.0)	10(50%) 42.8(10.6)	0.025 0.017		18 (94.7%) 26.6(1.71)		
Speech therapist (n/%) <i>(mean (SD) minutes a week)</i>	4(16.7%) 6.0(1.9)	6(30%) 10(3.8)	0.317 0.136		5(26.3%) 9.5(4.0)		
Occupational Therapy (n/%)	1(4.2%)	4(20%)	0.083		-		

(mean (SD)	7.05 (7.1)	12.5(7.7)	0.102	
minutes a week)				
Dietician				-
(n/%)	0(0%)	1(5%)	0.317	
(mean (SD)	0	1.88 (1.9)	0.317	
minutes a week)				
Social work				-
(n/%)	0(0%)	1(5%)	0.317	
(mean (SD)	0	0.25(0.25)	0.317	
hours a week)				

Table 2: Medication median scores and IQR's=IQR75-IQR25, 95% CI). Allied therapies n= amount of patients and percentage. Mean minute/hours per patients per week with SD

* Wilcoxon

** Mann-Whitney

Cholinesterase inhibitors (CHEI) were started in 13 patients (54.2%) in the intervention group, whereas in the control group cholinesterase inhibitors were stopped in 4 patients (21.1%). Atypical antipsychotics were started in 3 patients (12.5%) of the intervention group, whereas atypical antipsychotics were stopped in 4 patients (21.1%) in the control group. Four patients (16.7%) of the intervention group received tricyclic antidepressants (TCAs) during the inpatient phase of the intervention, whereas in 4 patients (21.1%) of the control group TCAs were stopped.

Scores Intervention PfP group							
Test score	Baseline median(IQR)	6 weeks median(IQR)	p-value *	3 months median(IQR)	p-value *	2 years median(IQR)	p-value **
<i>Primary outcome</i>							
ALDS	59.28 (31.09-72.29)	69.89# (58.05-78.34)	0.000	70.03# (50.21-80.46)	0.005	62.61 (34.87-71.99)	0.140
<i>Secondary outcomes</i>							
SCOPA-SPES	23.50 (16.5-29.25)	19.00# (16-23)	0.005	20.50 (16.25-27.0)	0.316	24.00 (20.0-35.0)	0.462
<i>Subitems</i>							
<i>Motor evaluation</i>	9.00 (6.25-13.5)	7.00# (6.0-10.0)	0.100	9.50 (6.5-12.0)	0.831	12.00 (7.0-15.0)	0.786
<i>ADL</i>	10.50 (9.0-14.0)	9.00# (8.0-13.0)	0.048	9.50 (8.0-12.5)	0.944	11.0 (8.0-17.0)	0.495
<i>Motor complications</i>	2.00 (0.0-3.75)	1.00# (0.0-3.0)	0.008	1.00 (0.0-2.0)	0.010	4.00 (3.0-5.0)	0.680
SCOPA-COG	22.00 (14.0-26.75)	28.00# (22-31)	.000	27.5 (20.25-30.75)	.0887	20.00 (11.0-27.0)	0.039
<i>Subitems</i>							
<i>Memory</i>	6.00 (4.0-9.0)	8.00# (7.0-10.0)	0.002	9.00# (7.0-10.0)	0.604	5.00 (5.0-7.0)	0.073
<i>Attention</i>	3.00 (1.5-4.0)	4.00# (3.0-4.0)	0.067	4.00 (3.0-4.0)	0.762	2.00 (1.0-4.0)	0.457
<i>Executive functioning</i>	9.00 (4.25-10.0)	11.00# (8.0-12.0)	0.002	9.00 (4.0-11.0)	0.015	9.00 (4.0-11.0)	0.009
<i>Visuospatial functioning</i>	4.00 (3.0-5.0)	4.00 (3.0-6.0)	0.230	5.00# (3.0-7.0)	0.051	3.00 (1.0-7.0)	0.263
NPI	2.00 (1.0-6.0)	0.50# (0.0-2.50)	0.001	0.00 (0.0-1.00)	0.046	0.50 (0.0-1.25)	0.082
<i>Hallucinations (n/%)</i>	10(42%)	6# (25%)	0.014	7 (35%)	0.157	5 (38%)	0.753
<i>Depression (n/%)</i>	7 (29%)	4# (17%)	0.083	1# (5%)	0.083	1 (8%)	0.112
<i>Delusions(n/%)</i>	2 (8.3%)	2(8.3%)	1.00	1# (5%)	0.317	0#	0.392
BDI	11(9.75-15.0)	7# (6.0-10.0)	0.00	9(7.5-12.5)	0.113	12(11.0-14.0)	0.032
Patients living independently at home (n, %)	-	20 (83%)		20 (83%)		13 (65%)	


Table 3: Scores are median scores and range IQR25-IQR75, 95% CI.

suggest improvement over time

suggest worsening over time

* Wilcoxon

** Friedman



* not enough patients to create a boxplot (n=2).

Figure 1: Sub-analysis: Differences in the median ALDS within the intervention PfP group, comparing patients who could return home (83%) to patients finally admitted to a nursing home (17%).

References Supplements

1. Keus SHJ; Hendriks HJM; Bloem BR; Bredero-Cohen AB; Goede CJT de; Haaren M van; Jaspers M; Kamsma YPT; Westra J; Wolff BY de; et al. KNGF-richtlijn Ziekte van Parkinson. *Nederlands Tijdschrift voor Fysiotherapie* (2004) 114, (suppl):1-88.
2. Domingos J, Keus SHJ, Dean J, de Vries NM, Ferreira JJ, Bloem BR. The European Physiotherapy Guideline for Parkinson's Disease: Implications for Neurologists. *J Parkinsons Dis* (2018) 8:499–502. doi: 10.3233/JPD-181383
3. Kalf JG, de Swart BJM, Bonnier M, Hofman M, Kanters J, Kocken J, Miltenburg M, Bloem BR, Munneke M. Logopedie bij de ziekte van Parkinson, een richtlijn van de Nederlandse Vereniging voor Logopedie en Foniatrie. Woerden/Den Haag (2008).
4. van der Marck MA, Kalf JG, Sturkenboom IHWM, Nijkraak MJ, Munneke M, Bloem BR. Multidisciplinary care for patients with Parkinson's disease. *Parkinsonism Relat Disord* (2009) 15 Suppl 3:S219-23. doi: 10.1016/S1353-8020(09)70819-3
5. Ingrid Sturkenboom, Marjolein Thijssen, Jolanda Gons-van Elsacker, Irma Jansen, Anke Maasdam, Marloes Schulten, Dicky Vijver-Visser, Esther Steultjens, Bas Bloem, Marten Munneke. 'Ergotherapie bij de ziekte van Parkinson. Een richtlijn van Ergotherapie Nederland.' Utrecht/ Den Haag (2008).
6. van Asseldonk MJMD, Dicke HC, van den Beemt BJW, van den Berg DJ, ter Borg S, Duin GM, Govers SLHM, van Teeffelen JJ, Hoff JI, van Harten B, et al. Richtlijn diëtetiek bij de ziekte van Parkinson. Den Haag (2012).